Modeling and simulation in clinical pharmacology and dose finding.

Area of Science:

• Pharmacometrics and Systems Pharmacology
• Regulatory Science
• Drug Development

Background:

• The European Medicines Agency/European Federation of Pharmaceutical Industries and Associations Modeling and Simulation (M&S) workshop addressed key areas in pharmaceutical development.
• Breakout session 2 focused on the application and acceptance of M&S in regulatory decision-making.

Purpose of the Study:

• To define the appropriate use and acceptance criteria for M&S in dose-regimen selection.
• To explore the potential of M&S for registering dosing regimens without requiring dedicated clinical studies.

Main Methods:

• Discussion of two primary topics: M&S for dose-regimen selection and M&S for registration without specific studies.
• Presentation of industry and regulatory viewpoints for each topic.
• Illustration of concepts through case examples.

Main Results:

• Exploration of the conditions under which M&S is utilized and accepted by regulatory authorities.
• Discussion on the feasibility of registering dosing regimens using M&S, potentially reducing the need for certain trials.
• Insights into practical applications via case studies.

Conclusions:

• M&S holds significant potential to optimize dose-regimen selection processes.
• The strategic application of M&S may enable regulatory approval of dosing regimens, streamlining drug development.
• Further dialogue between industry and regulators is crucial for advancing M&S acceptance.